Soc. Generale Knock-Out MRK/ DE000CL7GXG3 /
5/29/2024 1:27:58 PM | Chg.+0.120 | Bid2:08:28 PM | Ask2:08:28 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
6.450EUR | +1.90% | 6.470 Bid Size: 10,000 |
6.480 Ask Size: 10,000 |
MERCK KGAA O.N. | 104.3929 - | 12/31/2078 | Call |
GlobeNewswire
1:02 PM
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
1:00 PM
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, ...
GlobeNewswire
8:00 AM
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
GlobeNewswire
5/7
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
5/6
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
3/4
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
12/21/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
12/14/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
10/17/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA